Options for Chemotherapy and Scoring Response and Relapse.

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Amyloid light chain (AL) amyloidosis treatment has evolved significantly.
• High-dose melphalan and stem cell transplantation are standard for eligible patients.
• Most patients require effective low-intensity induction therapy at diagnosis.

Purpose of the Study:

• To review current chemotherapy approaches for AL amyloidosis.
• To highlight the role of bortezomib in induction therapy.
• To emphasize the importance of clinical trials for novel treatments.

Main Methods:

• Review of current literature and treatment guidelines for AL amyloidosis.
• Analysis of treatment efficacy and tolerability in different patient populations.
• Discussion of limitations in current therapeutic options.

Main Results:

• Bortezomib-based regimens are effective induction therapy for most AL amyloidosis patients.
• Immunomodulatory agents are generally reserved for later lines of therapy due to poor tolerability, especially in cardiac amyloidosis.
• No FDA-approved therapies currently exist for AL amyloidosis.

Conclusions:

• Bortezomib-based induction therapy is a cornerstone for patients not eligible for stem cell transplantation.
• Careful patient selection and consideration of comorbidities are essential.
• Participation in clinical trials is strongly encouraged for patients with AL amyloidosis.